Boston Scientific to Buy Penumbra for $14.5 Billion in Thrombectomy Push

M&A · PartnershipCorporate Action Impact 4
โดย Zacks Investment Research·US·Read original
Summary · why it matters

Boston Scientific has agreed to acquire Penumbra for $14.5 billion, a deal that would expand the company's presence in thrombectomy, the market for removing blood clots and blockages from blood vessels. The transaction is expected to close in the second half of 2026, subject to customary closing conditions including regulatory clearances, and will be integrated into Boston Scientific's Cardiovascular division. The company said the deal is expected to weigh on adjusted earnings per share by 6-8 cents in the first full year after closing, with the earnings impact improving thereafter. Earlier this year Boston Scientific acquired Valencia Technologies, adding the eCoin system to its Urology portfolio and expanding into implantable tibial nerve stimulation, a deal expected to have an immaterial impact on adjusted earnings per share in 2026 though more dilutive to GAAP earnings. The company also acquired full ownership of Nalu Medical, paying approximately $523 million upfront for the remaining stake, net of cash acquired, after holding an equity stake of approximately 9% since 2017, with the business integrated into the Neuromodulation division. In 2025, closed acquisitions added 340 basis points to sales, contributing to 15.8% organic revenue growth, while the additions of Bolt Medical and SoniVie advanced its coronary and peripheral disease and interventional cardiology strategies.

Impact on stocks 4

Brain-Computer Interface▲ · 1 stocks
Boston Scientific Corp
BSX
▲ PositiveCapitalrelevance

Boston Scientific agreed to acquire Penumbra for $14.5 billion, expanding its thrombectomy presence in its Cardiovascular division.

Aging Population▲ · 1 stocks
Penumbra Inc
PEN
▲ PositiveCapitalrelevance

Penumbra is being acquired by Boston Scientific for $14.5 billion, a takeover of the company.

Biotech & Genomic Medicine▲ · 1 stocks
Robotics & Physical AI▲ · 1 stocks

Theme Impact 1

Related news

▲

Amgen Fair Value Target Rises to US$388.03 as Analysts Split on Pipeline Risks

Amgen's updated analyst model lifted its fair value price target to US$388.03 from a prior US$371.93, with the revenue growth assumption rising to 3.50% from 2.93%, the net profit margin assumption moving to 25.15% from 24.84%, the future P/E multiple changing to 25.1x from 24.6x, and the discount rate shifting to 7.96% from 7.70%. The revision reflects a split analyst view, with UBS, Argus, TD Cowen, Scotiabank and Oppenheimer raising their Amgen price targets into a US$420 to US$460 range on the strength of a strong product portfolio, Q2 beats and higher guidance. Wells Fargo and Piper Sandler lifted their targets to US$435, citing external survey work and prescription data they believe support higher long term sales potential for cholesterol and cardiovascular products such as Repatha and Lipfendra. On the bearish side, HSBC downgraded Amgen to Hold and cut its target to US$425 from US$445, saying the stock price now more closely matches its assessment of fair value with limited near term upside, while BMO Capital shifted to a neutral Market Perform stance even with a higher US$450 target, citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile and sales potential of MariTide.
AMGN ▲
Biotech & Genomic Medicine
Simply Wall St·8hRead more →
▲

Edwards Lifesciences Targets $2 Billion TMTT Business by 2030 as CMS Expands TAVR Access

Edwards Lifesciences outlined a structural heart growth plan that targets more than US$2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by its PASCAL, EVOQUE, and Sapien M3 technologies. The plan sits alongside updated Medicare coverage that could enable 100 to 200 additional U.S. centers to perform TAVR procedures, reinforcing the company's transcatheter ecosystem. Edwards' broader narrative projects $8.5 billion in revenue and $2.2 billion in earnings by 2029, requiring 9.3% yearly revenue growth and an earnings increase of about $1.2 billion from $979.9 million today. Three fair value estimates from the Simply Wall St Community cluster between US$91.47 and US$100.96 per share, against a $100.96 fair value that implies 14% upside to the current price. The company still faces risks around margins, tariffs, and competitive pressure in international markets.
EW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·12hRead more →
▼impact 4

Novartis Shares Plunge 10% as Del-desiran Fails Late-Stage Trial

Novartis shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1, marking its third clinical setback in a week. The earlier failures involved the cardiovascular drug pelacarsen and a pause of eight trials of the cell therapy rap-cel following three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history. Barclays had estimated peak annual sales of about $3.1 billion for del-desiran and assigned the drug a 60% probability of success after positive mid-stage results, and the failure raises questions about the $12 billion Avidity acquisition that brought the drug into Novartis' pipeline. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030, while the company reported successful late-stage results for remibrutinib in multiple sclerosis and expects more data later this year.
NOVN.SW ▼
Biotech & Genomic Medicine ▼
CNBC·1dRead more →
© 2026 MarketDXNews